Test predicts which patients with prostate cancer are most likely to develop long-term side effects from radiation therapy
Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which patients with prostate cancer are at higher risk of developing long-lasting urinary side effects after receiving radiation therapy. The test, called PROSTOX, is the first of its kind to use microRNAs to predict toxicity from cancer therapy. It could help prevent the burden of long-term complications by identifying patients most at risk before treatment even begins. In a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, the UCLA team validated PROSTOX’s ability to predict long-term urinary side effects, which can include urinary tract pain, blood in the urine, increased frequency of urination, and urinary urgency or leakage. The researchers also found that different genetic factors are linked to different types of side effects, reinforcing the need for more personalized…
